Table 3.
EGFR Status Subgroup Analysis of the Clinical Features of Study Patients
| EGFR Negative (N = 13) |
EGFR Positive (N = 28) |
P | |
|---|---|---|---|
| Sex, N (%) | .460 | ||
| Male | 9 (69.2) | 16 (57.1) | |
| Female | 4 (30.8) | 12 (42.9) | |
| Median age (range), years | 66 (51-85) | 57 (36-82) | .147 |
| KRAS status, N (%) | .026 | ||
| Wild type | 9 (69.2) | 9 (32.1) | |
| Mutated | 4 (30.8) | 19 (67.9) | |
| Tumor sidedness | 1.000 | ||
| Left side | 12 (92.3) | 24 (85.7) | |
| Right side | 1 (7.7) | 4 (14.3) | |
| UGT1A1 status | .765 | ||
| 6/6 | 11 (84.6) | 22 (78.6) | |
| 6/7 | 2 (15.4) | 5 (17.9) | |
| 7/7 | 0 (0.0) | 1 (3.6) | |
| Irinotecan dose, N (%), mg/m2 | .880 | ||
| 260 | 3 (23.1) | 4 (14.3) | |
| 240 | 2 (15.4) | 3 (10.7) | |
| 210 | 1 (7.7) | 2 (7.1) | |
| 180 | 7 (53.8) | 18 (64.3) | |
| 120 | 0 (0.0) | 1 (3.6) | |
| Best objective response, N (%) | .027 | ||
| PR | 3 (23.1) | 1 (3.6) | |
| SD | 8 (61.5) | 12 (42.9) | |
| PD | 2 (15.4) | 15 (53.6) | |
| DCR, N (%) | 11 (84.6) | 13 (46.4) | .021 |
| AEs | .055 | ||
| Grade ≧3 | 11 (84.6) | 15 (46.4) | |
| Grade <3 | 2 (15.4) | 13 (53.6) |
EGFR, epidermal growth factor receptor; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; AEs, adverse events.